CONNECT WITH US
HealthTech

HealthTech

FDA approves first factor XIa inhibitor for secondary stroke prevention

Medical Xpress logo

Published on

Add as a preferred source on Google
FDA approves first factor XIa inhibitor for secondary stroke prevention

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

The U.S. Food and Drug Administration has approved Sunharbo (asundexian) 50 mg tablets, in combination with antiplatelet therapy, to reduce the risk for stroke in adults following a recent mild-to-moderate noncardioembolic ischemic stroke or a high-risk transient ischemic attack (TIA).

Sunharbo is the first factor XIa inhibitor approved for use with antiplatelet therapy. However, concomitant use with medicines that are combined P-gp and strong CYP3A4 inducers is not recommended due to a decrease in Sunharbo's effectiveness. Furthermore, Sunharbo is not recommended in patients with moderate or severe hepatic impairment, nor is it approved for stroke prevention in patients with atrial fibrillation.

The approval is based on results from the OCEANIC-STROKE phase 3 study, in which 12,327 adults with a noncardioembolic ischemic stroke (NIH Stroke Scale ≤15) or high-risk TIA were randomly assigned to Sunharbo or placebo within 72 hours of symptom onset, in addition to antiplatelet therapy. Compared with placebo, Sunharbo 50 mg once daily significantly reduced the risk for ischemic stroke by 26% during a median treatment of 14.2 months.

The overall rate of major bleeding was similar between the groups, but was increased with Sunharbo in patients older than 75 years and during the first 90 days of treatment. Diarrhea was the most frequently reported adverse reaction (≥3% of Sunharbo-treated patients). Gastrointestinal bleeding occurred more often with Sunharbo than placebo.

, co-principal investigator of the OCEANIC-STROKE study at McMaster University, said in a statement.


Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.